Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | - |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Titan Pharmaceuticals Inc (PK) | TTNPW | OTCMarkets | Equity Warrant |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.0002 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.0002 |
| Trades | Volume | Avg Volume |
|---|---|---|
| 0 | 0.00 | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | 0.0002 | USD |
Titan Pharmaceuticals Inc (PK) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.38k | 6.91M | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News Titan Pharmaceuticals (PK)
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
TTNPW Historical
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| Titan Pharmaceuticals Inc. (TTNP.OB), based in South San Francisco, CA, is a specialty pharmaceutical company developing proprietary therapeutics utilizing its ProNeura implant drug delivery technology. ProNeura provides non-fluctuating levels of medication continuously over periods of six months to a year and is ideal for use in the treatment of select chronic diseases for which subdermal delivery may offer advantages over oral administration. Titan's lead product candidate is Probuphine, a novel, subdermal implant formulation of buprenorphine designed to provide six months of medication for the maintenance treatment of opioid dependence following a single administration. A final Phase 3 trial of Probuphine is in progress, with results expected by mid-2015. Successful completion is expected to provide the clinical data requested by the FDA, and permit resubmission of the NDA later in 2015. Probuphine, which is licensed to Braeburn Pharmaceuticals for the U.S. and Canadian markets, has the potential to be approved in the U.S. in the first half of 2016. Titan is also in the early stages of developing a ProNeura-based product for the treatment of Parkinson's disease, and also investigating opportunities with other chronic treatments. |
